|
|
|
|
|
03.03.26 - 22:36
|
Novo′s Latest Ozempic Ad Misleads Viewers, FDA Says (Bloomberg)
|
|
|
Less than a month after the US Food and Drug Administration said a TV advertisement for Novo Nordisk A/S' Wegovy weight-loss pill included “false or misleading” claims, the company was hit with a notice for its original blockbuster Ozempic....
|
|
|
03.03.26 - 21:31
|
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)
FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA
Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana
Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany
Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization of apitegromab and strategic advancement of key pipeline programs
Cash, cash equivalents, and marketable securities of $367.6 million as of December 31, 2025
Management to host conference call today at 8:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the release, the...
|
|
|
03.03.26 - 17:33
|
Novo Nordisk Aktie: Bewertung nun realistischer (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von Morgan Stanley:
Morgan Stanley habe die Aktie von Novo Nordisk A/S (ISIN: DK0062498333, WKN: A3EU6F, Ticker-Symbol: NOV, NASDAQ Kopenhagen-Symbol: NOVO B) von "underweight" auf "equal weight" hochgestuft, das Kursziel aber von 42 auf 40 USD gesenkt. [mehr]...
|
|
|
|
|
03.03.26 - 13:03
|
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA)
FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with discussion of remediation progress and no additional corrective actions requested by FDA
Scholar Rock plans to resubmit BLA upon successful FDA reinspection of Catalent Indiana
Apitegromab Marketing Authorisation Application (MAA) review ongoing, with EMA decision anticipated in mid-2026; European launch expected in H2 2026, starting with Germany
Secured new debt facility, providing up to $550 million in non-dilutive capital to support commercialization of apitegromab and strategic advancement of key pipeline programs
Cash, cash equivalents, and marketable securities of $367.6 million as of December 31, 2025
Management to host conference call today at 8:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDA...
|
|
|
|
|
|
|
03.03.26 - 11:52
|
Novo Nordisk Equal Weight (DPA-AFX)
|
|
|
LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Novo Nordisk mit einem Kursziel von 270 dänischen Kronen auf "Equal Weight" belassen. Die Nachfrage nach Wegovy als Abnehmpille sehe nach dem jüngsten Start weiter ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 14:00
|
Here Are Monday′s Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: The futures are trading lower after a dreadful Friday and week, one that could be laying the foundation for a larger and more intense sell-off. The combination of the sell-off in Nvidia Corp. (NASDAQ: NVDA), the much higher producer price index print, the ongoing confusion over the tariffs, and the weekend military ... Here Are Monday's Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More
The post Here Are Monday's Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More appeared first on 24/7 Wall St.....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
